GlassScriptPhysician profile
Anwer Baloch
NPI 1922062579
$3,663.21
in general payments reported to CMS, 2019-2025
17 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $301 · 2021: $557 · 2022: $809 · 2023: $868 · 2024: $641 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.87 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,230.19 | 2019-2025 | Aristada, Lybalvi |
| Janssen Biotech, INC. | $579.66 | 2022-2024 | Erleada, Imbruvica, Darzalex |
| Sobi, INC | $239.48 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $118.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $98.64 | 2019-2022 | |
| Dova Pharmaceuticals | $67.81 | 2019-2021 | |
| Amgen INC. | $66.19 | 2022-2023 | Xgeva, Vectibix, Nplate |
| Astrazeneca Pharmaceuticals LP | $59.57 | 2020-2025 | Enhertu |
| Pfizer INC. | $38.84 | 2020-2024 | |
| Bioxcel Therapeutics, INC. | $33.23 | 2023 | Igalmi |
| Livanova USA, INC. | $25.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.96 | 2020-2021 | |
| Neurelis, INC. | $23.80 | 2024 | Valtoco |
| Incyte Corporation | $16.16 | 2024 | Jakafi |
| Celgene Corporation | $14.44 | 2023 | Reblozyl |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $13.65 | 2021 | |
| Mirati Therapeutics, INC. | $13.48 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwer Baloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.